Overview of Antithrombin III

Quick Facts About Antithrombin III

Property	Description
Active ingredient	Antithrombin III Human
Form	Lyophilized powder for injection
Pharmacological class	Anticoagulants, Serine Protease Inhibitor
Common role	Regulates blood clotting (Inhibitor)
Origin	Plasma-derived (Human) or Recombinant

What Type of Medicine is Antithrombin III (ATIII)?

Antithrombin III (ATIII) is a specialized protein-based therapy classified by medical bodies as an Anticoagulant and a Plasma Coagulation Factor and Regulatory Protein. This medication is not a synthetic chemical but an alpha-2-glycoprotein that naturally occurs in human plasma, serving as the body's most critical physiological inhibitor of blood coagulation. The active compound, Antithrombin III Human, is functionally identified as a member of the serine protease inhibitor (Serpin) superfamily. This mechanism is clinically recognized as crucial for modulating the coagulation cascade, reflecting its unique and non-replaceable role in maintaining hemostasis.

Composition and Origin: Is Antithrombin III Plasma-Derived or Recombinant?

The medication is a single-ingredient product supplied as a lyophilized powder for injection specifically designed for intravenous administration. This therapeutic agent is unique as its source can vary: it is either purified directly from pooled healthy human plasma donations (plasma-derived Antithrombin III), or it is manufactured using advanced biotechnology (Recombinant Antithrombin III). Both origins are effective in delivering the active plasma glycoprotein to the patient, thus ensuring a stable supply for replacement therapy. This dual origin distinguishes it from many synthetic small-molecule drugs.

Antithrombin III's Role: How Does it Regulate Blood Clotting?

The primary job of Antithrombin III is to control and regulate the blood's clotting process by rapidly neutralizing key enzymes, preventing the formation of unnecessary and dangerous blood clots, or thromboembolism. It functions as a powerful coagulation inhibitor by acting as an "off switch" that targets the most potent factors in the coagulation cascade, specifically thrombin and Factor Xa. Antithrombin III is required for the inhibition of activated clotting factors, maintaining the critical balance necessary for healthy blood flow. The general therapeutic goal is to restore the natural anti-clotting balance in conditions characterized by a functional deficiency of this key regulatory protein.

Regulatory References

NIH MedlinePlus

What side effects are possible with Antithrombin III?

Possible Side Effects and Safety Information

Antithrombin III (ATIII) is associated with an officially documented safety profile, with potential adverse reactions and safety patterns primarily related to its function as a regulatory anticoagulant protein. The safety information is classified based on clinical evidence from regulatory sources.

Documented Adverse Reactions and Frequencies

Based on official labeling, the most common adverse reactions (reported in ge 5% of patients in clinical studies) involve the nervous and gastrointestinal systems. These include dizziness, chest discomfort, nausea, dysgeusia (change in taste), and pain in the form of cramps.

Adverse effects are documented across various System-Organ Classes, including Gastrointestinal Disorders (nausea, dysgeusia), Nervous System Disorders (dizziness, tremor), and General Disorders (chills, fever, hypersensitivity).

Serious Safety Considerations

The most significant safety consideration is the risk of hemorrhage (bleeding), which is noted as a major risk in regulatory warnings, especially when the product is used with concurrent anticoagulation. Severe hypersensitivity reactions, including the potential for anaphylaxis, have also been reported and are listed as a serious concern.

Population-Specific Notes and Constraints

Specific safety considerations exist for certain groups. A higher incidence of bleeding has been reported in geriatric patients, particularly women, when Antithrombin III is co-administered with heparin. Furthermore, since the plasma-derived product is manufactured from human blood, it carries a theoretical risk of infectious agent transmission (e.g., viruses, CJD agent), despite stringent viral inactivation and removal procedures. The concurrent use of ATIII enhances the anticoagulant effect of heparin, which necessitates specific management notes to mitigate the risk of bleeding.

Overdose and Emergency Response

Overdose and When to Seek Help

This information is based strictly on officially documented overdose profiles in government regulatory sources, detailing manifestations and regulator-mandated emergency actions.

Documented Overdose Manifestations

Classification	Regulatory Statement/Manifestation
Primary Clinical Sign	Hemorrhage (excessive bleeding), resulting from an Exaggerated Anticoagulant Effect.
Laboratory Confirmation	Functional Plasma Antithrombin (AT) Activity Level >120% is the marker for over-administration.

Life-Threatening Outcomes and Emergency Actions

The regulatory label documents two situations requiring immediate attention:

Acute Reaction: Anaphylaxis and severe Hypersensitivity Reactions are documented risks. Symptoms may include generalized urticaria, wheezing, hypotension, or tightness in the chest.
Required Action: If signs of a hypersensitivity reaction occur, the infusion must be discontinued immediately, and appropriate emergency treatment must be administered.

Antidote and Management

The official regulatory documentation states that no specific antidote is known for Antithrombin III overdose. Management is centered on symptomatic and supportive treatment. For confirmed over-administration (AT activity >120%), official guidelines mandate a 30% decrease in the maintenance infusion dose followed by laboratory rechecking of AT activity.

Therapeutic Uses of Antithrombin III

What Antithrombin III Treats: Main Uses and Benefits

Antithrombin III (AT-III) is commonly used to help manage and control symptoms associated with acute or episodic changes in the blood's clotting ability. The core therapeutic domain of Antithrombin III is applied across conditions presenting with acute episodes, specifically in the management of hereditary antithrombin deficiency. This inherited condition is associated with acute or episodic changes, which can produce significant symptomatic burden related to heightened physiological activity.

Antithrombin III is used across domains where additional symptomatic support is needed, primarily in clinical settings that involve acute or unstable symptom patterns related to hereditary antithrombin deficiency, which are linked to organ-specific functional stress. Official indications include the use of this therapy in clinical scenarios involving thromboembolism (blood clots) and for use around the time of surgery or childbirth (peri-operative and peri-partum).

Antithrombin III is a therapeutic agent relevant in contexts involving heightened systemic burden. It may assist with symptom clusters that may become intense or disruptive. The use of this agent supports the patient during difficult episodes by easing distress and helps with maintaining functional stability. It contributes to improved comfort by easing the overall symptom burden and is commonly used to help with addressing symptoms that interfere with daily comfort. This therapy may help patients cope more steadily with symptom fluctuations.

Quick Fact: Relief is relevant in contexts involving heightened systemic burden and symptoms that create noticeable physiological strain.

Eligibility and Restrictions for Use

The eligibility for using Antithrombin III is strictly defined by regulatory authorities and centers on the patient's underlying condition and specific risk factors.

Eligibility Scope

Classification	Population/Condition
Allowed (Indicated Use)	Adult and pediatric patients with Hereditary Antithrombin Deficiency (hATd).
Contraindicated	Patients with known hypersensitivity to the drug or any component of the formulation. Patients with known allergy to goat proteins must not use the recombinant product (ATryn).

Age and Physiological States

Category	Regulatory Status
Age Groups	Indicated for both adult and pediatric patients with hATd for the approved uses.
Pregnancy/Lactation	Use is specifically indicated for the prevention of peri-partum (around the time of childbirth) thromboembolic events in hATd patients. Information regarding its excretion into human milk during lactation is not established.
Restrictions	Use with concomitant Heparin requires close laboratory monitoring, as the Antithrombin III treatment enhances Heparin's effect, potentially requiring a reduction in Heparin dose. Use in infants for unapproved conditions carries cautionary statements in some regulatory documents.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Antithrombin III (ATIII) is highly specific and is defined by its relationship with other agents that modify blood coagulation, as documented in official regulatory sources.

Drug-Drug Interactions: Pharmacodynamic Reinforcement

Interacting Substance	Interaction Classification	Official Restriction or Constraint
Heparin (Unfractionated or Low Molecular Weight)	Clinically Significant Pharmacodynamic Reinforcement	Mandatory reduction of heparin dosage and close monitoring of coagulation tests (e.g., aPTT).

The most significant and officially documented drug-drug interaction is with heparin. Regulatory prescribing information states that the anticoagulant activity of heparin is enhanced by the co-administration of Antithrombin III, resulting in a risk of increased anticoagulant effect. To manage this effect, official regulatory guidelines mandate close monitoring of coagulation parameters. This also requires a procedural constraint: the dose of co-administered heparin must be appropriately reduced during treatment with ATIII, a condition explicitly written in official drug labels.

Absence of Other Documented Interactions

The official interaction profile is further characterized by the absence of documented effects in common interaction domains. Regulatory sources do not specify interactions involving the Cytochrome P450 (CYP) enzyme system or other drug transport proteins. Furthermore, there are no documented mandatory timing separation requirements or specified interactions with food, alcohol, herbal products, or dietary supplements in the official regulatory documents.

Mechanism of Action

Irreversible Neutralization of Clotting Enzymes

Antithrombin III ( AT-III) is a protein belonging to the serpin (serine protease inhibitor) family that acts as an irreversible inhibitor of key clotting enzymes, primarily Thrombin (Factor IIa) and Factor Xa. It permanently removes these active procoagulant factors from circulation by forming a stable, covalent complex with their active sites. This action initiates a crucial sequence of events that suppresses the downstream cascade leading to fibrin formation.

Catalytic Acceleration of Inhibitory Action

The inhibitory activity of AT-III is dramatically accelerated by binding to heparin (or endogenous heparan sulfate) which acts as a catalytic template. This binding causes an allosteric conformational change in AT-III, increasing its reactivity toward Thrombin and Factor Xa by hundreds of times. This accelerated reaction rate allows for the rapid dampening of heightened coagulation pathway activation.

Systemic Modulation of Fibrin Formation

By inhibiting critical enzymes at multiple steps of the coagulation cascade, the mechanism of AT-III exerts broad, systemic modulation of the coagulation pathway's activity. This results in a reduction in the conversion of fibrinogen to fibrin, which is the main structural component of a clot. This regulatory action constrains the propagation of clot material, which establishes a mechanism for the modulation of hemostatic activity.

Dosage and Administration Information

Instruction Map: How to use Antithrombin III — Official Administration Guidelines

This map details the instructions for administering Antithrombin III, excluding all therapeutic, safety, and mechanism-related content.

Administration Scope

Feature	Instruction
Route of administration	Intravenous (IV) infusion only.
Dosing schedule	Dosing is individualized using a weight-based formula that incorporates the patient’s baseline functional Antithrombin (AT) level. The required units are calculated to achieve and maintain a therapeutic target range, typically 80% to 120% of normal plasma level.
Timing in relation to meals (if applicable)	Not applicable; administration is by intravenous infusion.
Preparation requirements (if applicable)	The lyophilized powder must be reconstituted with the specified diluent at room temperature. The solution must be administered within 3 hours and should not be refrigerated after preparation.
Age-group administration rules	The dosing formula applies to both adult and pediatric patients as it is adjusted by body weight (kg). Specific formula modifications are noted for pregnant women receiving peripartum treatment.
Missed-dose rules	Subsequent doses are strictly governed by the measured trough AT level achieved with the preceding dose, rather than a fixed schedule.
Special procedural conditions	The reconstituted solution must be administered alone, without mixing with other agents. The full dose is typically infused over 10 to 20 minutes.

Instruction Classifications (High-level)

Classification	Detail
Administration method type	Intravenous (IV) Infusion.
Frequency pattern	As-needed (individualized); administered with a loading dose followed by maintenance doses approximately every 24 hours, strictly based on laboratory monitoring.
Basis of instructions	Prescribing guidelines.
Use-context constraints	Requires continuous monitoring of functional AT levels (baseline, peak, trough, and at least every 12 hours) to guide dose adjustment and maintain the target range for the treatment course (e.g., 2 to 8 days).

Resulting Procedural Structure

Official Step Sequence:

Calculate the individualized loading dose.
Reconstitute the powder.
Administer via IV infusion.
Monitor AT levels (trough/peak).
Adjust and continue maintenance dosing for the prescribed duration.

Connection to the overall use protocol: The instructions mandate a highly procedural and supervised administration in a clinical setting, defining a precise sequence from individualized dose calculation to controlled intravenous infusion. This protocol is sustained by a requirement for frequent laboratory monitoring, where the measured functional AT level directly dictates the continuation and adjustment of the maintenance doses. These steps collectively ensure that the administration method, dose, and frequency strictly adhere to established standards.

Recent Clinical Evidence

Antithrombin III Research Evidence Overview

This overview explains the types of studies that have been studied for Antithrombin III, what areas research has explored, and what remains uncertain, based on official regulatory and scientific findings. This information is purely descriptive and does not offer medical advice.

Evidence for Use in Hereditary Antithrombin Deficiency

Antithrombin III was evaluated in research as a treatment for individuals born with Hereditary Antithrombin Deficiency (hATd), a rare, inherited condition. Research examined the use of this treatment during times when the risk of blood clots is heightened, such as around surgery (peri-operative) or childbirth (peri-partum). Studies primarily examined the prevention of serious blood clots, known as venous thromboembolism (VTE), and tracked the maintenance of functional Antithrombin levels.

Findings describe patterns observed where the therapy was observed to affect the balance of the blood's natural clotting inhibition. However, due to the rarity of the condition, the research base is limited by modest sample sizes in prospective trials. Detailed information about the long-term effects are not fully established, and follow-up durations were limited in the original regulatory trials.

Research Landscape in Acquired Antithrombin Deficiency

A separate and larger body of research was studied for the use of Antithrombin III in acquired conditions, specifically in critically ill adults with illnesses like Severe Sepsis or Disseminated Intravascular Coagulation (DIC). This research consists of numerous Randomized Controlled Trials (RCTs) and meta-analyses.

Studies explored major outcomes, including the effect on all-cause mortality and the incidence of bleeding events. Findings were mixed across many of these large trials, especially concerning the effect on the primary outcome of mortality. This variability means the certainty remains low for routine use in this patient group. The evidence quality varies across studies, and the heterogeneity (differences in patient groups) complicates the synthesis of results.

Frequently Asked Questions (FAQ)

Common questions about Antithrombin III (FAQ)

Q: Is Antithrombin III the same as just 'antithrombin' that's already in the body?

According to official regulatory documents, the medication contains the human Antithrombin (AT) protein. This protein is naturally found in human plasma and acts as the body's primary inhibitor of a key clotting factor called thrombin. The drug is intended to function as a replacement for this natural protein to restore proper anti-clotting activity.

Q: What is the main difference between Antithrombin III and heparin?

Antithrombin III is the protein that works to inactivate clotting factors in the blood. In contrast, heparin is a separate substance that must bind to Antithrombin III to act as a cofactor or accelerator. Official prescribing information highlights that this process is necessary for Antithrombin III to function effectively.

Q: How long do the effects of Antithrombin III last?

Based on official product information, the functional biologic half-life is reported to be approximately 3.8 days. The half-life is the time it takes for the concentration of the drug to fall to 50% of its highest level in the body.

Q: Is Antithrombin III treatment temporary or long-term?

Regulatory documents describe this treatment as temporary, intended for acute episodes or around times of high risk. For instance, the Antithrombin level is typically maintained for only 2 to 8 days during periods surrounding surgery or childbirth, depending on the individual clinical situation.

Q: Can I take other prescription medications while using Antithrombin III?

Official information indicates that taking Antithrombin III with other medications that prevent blood clots, such as aspirin or other anticoagulants, can increase the risk of bleeding. Close medical monitoring is necessary whenever these types of prescription drugs are administered together to manage the enhanced anti-clotting effect.

Q: Do people need to be tested for an Antithrombin III deficiency before treatment?

Yes, official documents indicate that the diagnosis of Antithrombin III deficiency is confirmed through specific blood tests. Furthermore, a patient's baseline functional Antithrombin level must be measured and used to calculate the individualized dose of the medication.

Q: What happens to Antithrombin III after it is given?

The Antithrombin III protein performs its job by forming a stable covalent complex with the clotting factors it targets. This process permanently inactivates the clotting factors, and the resulting complex is eventually cleared by the body.

Q: Is Antithrombin III used for all types of blood clots?

The product's official indication is specific: it is used for the treatment and prevention of thromboembolism (blood clots) in patients diagnosed with hereditary Antithrombin deficiency. This treatment is approved for managing clots related to hereditary deficiency, particularly around periods of high risk, such as surgery or childbirth.

Q: Does Antithrombin III affect the results of blood tests?

Yes, the medication affects the results of coagulation tests, which is why official guidelines mandate frequent monitoring of functional plasma Antithrombin levels to guide dosing. It is also noted that certain other medicines may affect the results of the Antithrombin III blood test itself.

Q: Is Antithrombin III considered a standard treatment for hereditary deficiency?

Official regulatory information describes the medication as the specific human Antithrombin (AT) replacement product. It is indicated for the treatment and prevention of blood clots in patients diagnosed with hereditary antithrombin deficiency.

Q: Is Antithrombin III a common drug?

Antithrombin III is primarily indicated for hereditary antithrombin deficiency, which is considered a rare condition. According to official scientific reviews, the incidence of this deficiency is low, generally estimated to be between 1 in 2,000 and 1 in 5,000 people in the general population.

Q: What happens if a person has too much Antithrombin III?

Dosing is closely monitored to ensure Antithrombin levels remain within the therapeutic target range. If levels exceed the therapeutic target range, the most significant risk noted in official safety information is hemorrhage (severe bleeding), as this may be a sign of excessive anti-clotting activity.

Q: Does Antithrombin III affect blood pressure?

Official product information notes that low blood pressure, known as hypotension, can be a potential symptom of a severe, acute hypersensitivity reaction to the medication. Additionally, chest discomfort/pain is listed as a common adverse reaction.

Q: Is Antithrombin III treatment painful?

Official safety documentation lists pain at the injection or infusion site as a common side effect associated with the intravenous administration.

Q: What does 'Antithrombin III deficiency' mean?

According to authoritative medical sources, Antithrombin III deficiency is a genetic disorder where a variant gene results in low levels of the Antithrombin III protein. Since this protein controls clotting, a deficiency causes the blood to clot more than normal, significantly increasing the risk of dangerous blood clots.

Q: Is there a generic version of Antithrombin III available?

The regulatory information does not confirm the existence or approval of a generic substitution for this specific product. Antithrombin III is supplied under multiple brand names internationally, such as THROMBATE III and ATryn.

Q: Are there different types or brands of Antithrombin III medicine?

Yes, official regulatory and prescribing information notes that Antithrombin III is marketed under multiple different brand names internationally, including THROMBATE III, ATryn, and Kybernin P. These products may differ in their source, being either plasma-derived or recombinant.

Q: Can Antithrombin III be used with dialysis?

Clinical research has examined the use of Antithrombin III supplementation during specific procedures, such as hemodialysis, particularly in patients with low Antithrombin levels due to liver problems. Clinical research suggests this use may help reduce the required amount of heparin during the procedure.

Q: Can a patient with liver problems use Antithrombin III?

Official and scientific literature recognizes that Antithrombin III levels can naturally be low in patients with conditions like liver failure or cirrhosis. Clinical research notes the medication has been studied to supplement these low levels in patients for specific medical procedures, such as hemodialysis.

How should Antithrombin III be stored and disposed of?

How to Store and Dispose of Antithrombin III

The storage and disposal of Antithrombin III (Human) must strictly follow regulatory guidelines to maintain product stability.

Storage Requirements

Unreconstituted Powder: Store the lyophilized powder at a temperature not exceeding 25 C (77 F). It must be kept in its original carton to protect the contents from light and must not be frozen.
Reconstituted Solution: The solution should be administered within 3 hours after reconstitution and must not be refrigerated during this time.

Disposal Instructions

Any unused portion of the reconstituted product must be discarded after the 3-hour limit. Needles, syringes, and all other materials used for preparation or administration must be placed in a puncture-resistant sharps container and disposed of according to federal, state, and local regulations.

Antithrombin III